Fundraising Fox

Tarveda Therapeutics

Watertown, US · Founded 2011 · Delaware corporation · 5 employees on LinkedIn · 3 known investors

Biotech

Founders & leadership

Tarveda Therapeutics was founded in 2011 by Omid Farokhzad, Robert S. Langer, Jr., Omid C. Farokhzad, and Robert S. Langer.

OFOmid Farokhzad
Omid FarokhzadinCo-founderChair and Chief Executive Officer at Seer
RS
Robert S. Langer, Jr.Co-founder
OCOmid C. Farokhzad
Omid C. FarokhzadinCo-founderChair and Chief Executive Officer at Seer
RS
Robert S. LangerCo-founder
AJ
Andrew J. FromkinExecutive
LA
Leila AllandinChief Medical Officer2016–2018
RW
Richard WoosterinPresident R&D and Chief Scientific Officer2016–2019

Board

JB
James BarrettBoard director
FT
Frank TortiBoard director
NK
Nilesh KumarBoard director
AS
Aymeric SallinBoard director
EM
Edwin M. KaniaBoard director

Investors · 3

+ND CapitalWoodside · $540K – $5.4M
Kendall Capital PartnersreportedBostonvia Robert Langer · board
New Enterprise Associates (NEA)reportedMenlo Park · $200K – $40M

Reported raises · per SEC filings

Form D private placements

$103.6M disclosed across 6 rounds · 2014–2021

▶$6MraisedSep 2021 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Aymeric SallinDirector
  • Michael MetzgerDirector
  • Brian RobertsExecutive Officer, Director
  • Nilesh KumarDirector
  • Dennis AusielloDirector
  • Guido MagniDirector
Offering amount
$6M
Amount sold
$6M
First sale
Sep 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15MraisedDec 2020 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Nilesh KumarDirector
  • Guido MagniDirector
  • Michael MetzgerDirector
  • Aymeric SallinDirector
  • Brian RobertsExecutive Officer
  • Dennis AusielloDirector
Offering amount
$15.4M
Amount sold
$15M
First sale
Dec 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$13.6MraisedDec 2019 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael MetzgerDirector
  • Aymeric SallinDirector
  • Robert LangerDirector
  • Nilesh KumarDirector
  • Guido MagniDirector
  • Omid FarokhzadDirector
  • Andrew J. FromkinExecutive Officer, Director
  • Dennis AusielloDirector
Offering amount
$13.6M
Amount sold
$13.6M
First sale
Dec 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$38MraisedFeb 2017 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Aymeric SallinDirector
  • Andrew FromkinExecutive Officer, Director
  • Robert S. LangerDirector, Promoter
  • Leila AllandExecutive Officer
  • Edwin M. KaniaDirector
  • James BarrettDirector
  • Dennis AusielloDirector
  • Nilesh KumarDirector
  • Richard WoosterExecutive Officer
  • Omid C. FarokhzadDirector, Promoter
  • Frank TortiDirector
Offering amount
$38M
Amount sold
$38M
Finders' fees
$720K
Proceeds to insiders
$2.5M
Placement agents
MTS Securities, LLC
First sale
Jan 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30MraisedFeb 2017 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew J. FromkinExecutive Officer, Director
  • Omid FarokhzadDirector
  • James BarrettDirector
  • Frank TortiDirector
  • Robert S. Langer, Jr.Director
  • Leila AllandExecutive Officer
  • Nilesh KumarDirector
  • Dennis AusielloDirector
  • Richard WoosterExecutive Officer
  • Aymeric SallinDirector
  • Guido MagniDirector
Offering amount
$30M
Amount sold
$30M
First sale
Jan 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1000KraisedMar 2014 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Omid C. FarokhzadDirector
  • Robert S. LangerDirector
  • James BarrettDirector
  • Richard WoosterExecutive Officer
  • Peter Barton HuttDirector
  • Aymeric SallinDirector
  • Edwin M. KaniaDirector
Offering amount
$1000K
Amount sold
$1000K
First sale
Feb 2014
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Funding sets up proof-of-concept trial for Tarveda's lead Pentarin next year | Fierce Biotechfiercebiotech.com · Feb 2017Tarveda Therapeutics Raises $30 Million in Series D Financing to Advance Pentarin Miniaturized Drug Conjugates | Business Wirebusinesswire.com · Feb 2017Tarveda Therapeutics Completes $30M Series D Financinggenengnews.com · Feb 2017Tarveda Therapeutics Secures $38M in Series C Financing - FinSMEsfinsmes.com · Jan 2016Blend Therapeutics Transforms into Tarveda Therapeutics and Bags $38 Million - BioSpacebiospace.com · Jan 2016Tarveda Therapeutics - Tech Company Profile - Gaebler.com Venture Capital Databasegaebler.com

Frequently asked questions

Who founded Tarveda Therapeutics?
Tarveda Therapeutics was founded by Omid Farokhzad, Robert S. Langer, Jr., Omid C. Farokhzad, Robert S. Langer in 2011.
Who are Tarveda Therapeutics's investors?
Tarveda Therapeutics's investors include +ND Capital, Kendall Capital Partners, New Enterprise Associates (NEA).
How much funding has Tarveda Therapeutics raised?
Tarveda Therapeutics has disclosed $103.6M raised across 6 rounds.
Where is Tarveda Therapeutics headquartered?
Tarveda Therapeutics is headquartered in Watertown, US.